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ABSTRACT 
EFFECTS OF GONADOTROPHIN RELEASING HORMONE ON GROWTH 
HORMONE RELEASE IN THE RAT Stephanie R. Goodman, Alan S. Penzias, and 
Ervin E. Jones. Section of Reproductive Endocrinology, Department of Obstetrics 
and Gynecology, Yale University School of Medicine, New Haven, CT. 
While abundant research has elucidated the role of growth hormone (GH) in the adult 
female reproductive system, the regulation of GH secretion has not been sufficiently 
explained. Previous studies have shown that gonadotrophin releasing hormone 
(GnRH) induces GH secretion independent of gonadotrophin secretion in a non¬ 
mammalian species, Carassius auratus (goldfish). The purpose of this study was to 
determine whether GnRH acts as a GH releasing factor in a mammal. Intrajugular 
silastic catheters were surgically placed in forty sexually mature female Sprague- 
Dawley rats. Approximately five days later, rats were randomly assigned to one of 
four experimental groups: I) normal saline, II) human GnRH, III) apomorphine plus 
GnRH, or IV) somatostatin plus GnRH. Blood (0.1 mL) was withdrawn through the 
catheter prior to treatment and then at 30, 60, 90, and 120 minutes. Samples were 
immediately centrifuged, and serum was frozen at -80°C. Red cells were suspended 
in a volume of heparinized saline equal to the removed serum and returned to the rat 
to maintain constant intravascular volume. Luteinizing hormone (LH) and GH were 
measured by radioimmunoassay, and results were analyzed using repeated measure 
ANOVA or student’s t-test where appropriate. Over time, GnRH caused significant 

elevations in both GH and LH levels (p< 0.0005). There was no statistically 
significant rise in the GH or LH levels for the saline control group (p>0.05). In 
addition, apomorphine caused a significant decrease in GnRH-induced LH secretion 
(p<0.05) but did not affect GH (p<0.0005). In contrast, somatostatin diminished 
the GnRH-induced GH rise but did not affect LH (p< 0.0005). Thus, this study 
provides evidence that in the rat GnRH causes secretion of GH in addition to LH. 
Because GH can be independently blocked without affecting LH and because LH can 
be separately diminished without changing GH, GnRH appears to act as an 
independent releasing hormone for both GH and LH. 
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The classical concept of neuroendocrine control of the anterior pituitary 
involves hypothalamic releasing factors and release inhibiting factors. These 
hormones control diverse events including reproduction, growth and development, 
internal homeostasis, and energy use and production. However, these factors were 
once considered specific such that one releasing factor and one inhibitor affect only 
one pituitary hormone. Thus, growth hormone (GH) secretion was thought to be 
under specific dual control—enhanced by growth hormone releasing factor (GRF) and 
inhibited by somatostatin.(1) 
More recently, hypothalamic releasing hormones have been shown to act on 
more than one pituitary hormone. For example, in normal healthy humans, 
thyrotrophin releasing hormone (TRH) causes release of both thyroid stimulating 
hormone (TSH) and prolactin (PRL) and has even been shown to release GH.(2) 
Although variable, TRH has also been shown to increase GH in healthy animals such 
as birds, reptiles, fish, sheep, and rats.(3) 
Other recent research has also demonstrated that TRH stimulates GH in certain 
diseases. One study of acromegalics showed that 500 ng of intravenous (IV) TRH 
stimulated GH in eight of 11 subjects.(4) This effect has been found in other 
syndromes including alcoholism, anorexia, cancer, cirrhosis, depression, diabetes, 
beta-thalassemia, and renal failure. Various explanations such as abnormal 
somatotroph receptors, hypothalamic dysfunction, and central aminergic dysfunction 
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have been forwarded to account for these findings.(3) None of these interpretations 
however considers TRH-induced GH a normal, biological response. Moreover, other 
hypothalamic peptides such as vasopressin, glucagon, neurotensin, endorphins, and 
metenkephalin have been reported to stimulate GH release.(5) The growing evidence 
that TRH and other mediators can stimulate GH secretion suggests that the control of 
hypothalamic-pituitary function is less specific than once thought. 
Similar to TRH, gonadotrophin releasing hormone (GnRH) has been reported 
to directly stimulate GH secretion in numerous clinical conditions such as acromegaly, 
anorexia nervosa, Klinefelter’s, diabetes mellitus, and major affective disorder. 
These responses have also been dismissed as abnormal or paradoxical due to deranged 
hypothalamic-pituitary control. Although the many studies documenting this effect 
were not randomized or placebo-controlled and often used different measures of a 
positive response, together they provide evidence for GnRH-induced GH secretion in 
pathologic conditions. 
Rubin et al showed that three of six acromegalic subjects given 100 ^tg of 
synthetic GnRH had increased levels of GH one hour after injection.(6) Another 
study of 16 patients with active acromegaly had similar results. As soon as 10 
minutes after a 25 /zg IV injection of GnRH, six of 16 subjects had a significant rise 
in plasma GH defined as 50% greater than baseline level and a net rise of more than 
10 ng/mL. No normal volunteers or patients with nonfunctioning adenomas exhibited 
this response. (7) Although these authors did not use a placebo-control or statistical 
analysis, they concluded that acromegalic patients had abnormal responses to GnRH 
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since GH secretion increased. 
A study of GH response to 0.1 mg IV GnRH in 11 females with anorexia 
nervosa showed that the increase in GH is not limited to patients with GH secreting 
pituitary tumors. Although the patients had elevated mean basal GH levels secondary 
to starvation, they were chosen for study since they all had exhibited TRH-induced 
GH secretion. Sixty minutes after receiving a bolus of GnRH, their mean GH 
concentration was significantly higher than baseline. Interestingly, the patients had 
impaired luteinizing hormone (LH) and follicle stimulating hormone (FSH) responses 
to the GnRH. Unfortunately, this study was neither placebo-controlled, patient- 
controlled nor blinded.(8) 
In patients with Klinefelter’s syndrome, GnRH similarly seems to stimulate 
GH. Nine of 16 patients given 50 /xg/m2IV GnRH had increased GH concentrations 
(defined as a rise from <5 ng/mL to >8 ng/mL) while no age-matched controls 
showed this response. These patients, unlike the anorexics, did not show a significant 
GH increase to TRH stimulation, but they had a normal GH response to insulin 
induced hypoglycemia. (9) 
Giampietro et al examined GH regulation in 16 diabetic males (nine Type I 
and seven Type II) and nine healthy male controls.(10) After a 25 ^g IV bolus 
injection of GnRH, seven diabetic patients (five Type I and two Type II) had a GH 
response within one hour (GH rise greater than the mean plus two standard deviations 
of basal levels and peak at least 5 ng/mL). This response was significantly higher 
than the response to TRH or saline, and no change in GH was observed in the 
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controls. Although GH regulation is considered abnormal in diabetes mellitus, there 
was no difference in baseline GH levels between subjects and controls. 
Amsterdam et al studied the effects of GnRH on 56 males and females with 
major affective disorder and 38 normal males and females.(11) GH, PRL, and TSH 
were measured after 250 fxg of a synthetic GnRH was administered as an IV bolus. 
This GnRH stimulation test produced statistically significant increases in GH levels 
when the data for all males (patients and controls) was combined. Separately, the 
levels did not achieve significance. In women, neither group had increased GH 
compared to baseline, but the GH levels in the bipolar group were higher than those 
in the unipolar group and controls. No significant differences were detected for PRL 
or TSH. 
Although this study was not placebo-controlled to remove the effect of the 
experimental stress, the rise in GH in male controls following GnRH administration 
led to the conclusion that this type of response can be seen in normal healthy 
individuals as well as in disease states. It remains unclear why GH did not increase 
in the women who were all in the follicular phase of their menstrual cycle and were 
not taking oral contraceptives. 
Further studies have involved both diabetics and depressed patients and have 
investigated the mechanism of GnRH-induced GH secretion. In a group of 16 male 
insulin-dependent diabetics, 18 unipolar depressed men, and nine healthy controls, 12 
diabetics and eight depressed subjects had stimulated GH levels significantly higher 
than baseline 40 minutes after 25 /xg IV GnRH.(12) No controls had this response, 

5 
unlike the findings of Amsterdam.(11) Nor did saline injection increase GH. 
Furthermore, 40 mg IV pirenzepine, a muscarinic antagonist, given 10 minutes prior 
to GnRH blocked the GH response in both groups but did not alter basal GH 
concentrations. Pirenzepine did not affect GnRH-induced LH or FSH.(12) 
Scant research on GnRH-induced GH secretion has been conducted in healthy 
humans. In eight healthy male volunteers, 25 /xg GnRH increased LH and FSH 
without changing GH.(13) Also, in four normal male subjects doses ranging from 25 
to 200 /xg GnRH significantly increased serum LH and FSH without affecting 
GH.(14) Despite these observations in small samples, the question of whether there 
is a normal direct connection between GnRH and GH release remains unanswered. 
Recent experimental work by Marchant et al in a non-mammalian species, 
Carassius auratus (goldfish), provides evidence that GnRH can release GH in normal 
physiologic states.(15) They found that intraperitoneal injections of salmon GnRH 
(0.1 /xg/g BW) elevated circulating levels of both GH and gonadotrophins in female 
goldfish after three and nine hours when compared to saline-injected controls. Five 
0.1 /xg/g BW injections of a mammalian GnRH analogue significantly increased 
goldfish body length compared to controls, suggesting increased GH secretion. 
The results of corresponding in vitro experiments were consistent with in vivo 
work. Using perifusion of pituitary fragments, Marchant et al showed that pulsed 
salmon GnRH stimulated GH secretion in a dose-dependent fashion and over a similar 
time course as gonadotrophins.(15) Their data suggest that GH and gonadotrophins 
are released by a common releasing hormone which acts at the pituitary level. In 
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vitro experiments also demonstrated that apomorphine (a dopamine receptor agonist) 
when combined with salmon GnRH decreased the gonadotrophin response with no 
effect on GH secretion. Somatostatin, a hypothalamic GH inhibitor, combined with 
salmon GnRH decreased the GH response without affecting gonadotrophin secretion. 
This research confirms GnRH-induced GH release and illustrates independent 
inhibition of GH and gonadotrophins. 
The present study provides a mammalian model similar to the goldfish. The 
purpose was to determine the in vivo effect of GnRH on LH and GH release in the rat 
and to further elucidate its regulation. Apomorphine was co-administered with GnRH 
to evaluate whether GnRH can specifically stimulate GH during LH inhibition. 
Similarly, somatostatin was given with GnRH to investigate the specific stimulation of 
LH while GH was suppressed. These experiments were designed to indicate whether 





Traditionally, hormones have been thought to act within one functional 
domain. For instance, FSH and LH function within the reproductive system and are 
not thought to affect energy production. GH, on the other hand, promotes linear 
skeletal growth through increased cartilage synthesis and functions metabolically by 
increasing insulin secretion, fatty acid release, and protein synthesis.(2) Contrary to 
previous thought, however, GH is now believed to play an active role in the 
reproductive system as well. These findings are substantiated by laboratory studies of 
granulosa cells and clinical studies of puberty, central precocious puberty, 
leiomyomata uteri, and ovulation induction. 
Cellular Effects of Insulin Like Growth Factors 
Insulin like growth factor-I (IGF-I or somatomedin-C) is a polypeptide which 
both mediates the effects of and is stimulated by GH. Most circulating IGF-I is 
synthesized in the liver, and, perhaps not surprisingly, a study of rat IGF-I 
messenger-RNA (mRNA) distribution in various tissues found the highest levels in the 
liver. Significant for the present study, the next highest concentrations were found in 
the uterus and ovary. Blood, lung, kidney, heart, and skeletal muscle all had 
significantly lower levels.(16) These findings indicate tissue specificity of growth 
factor expression and may even reflect its functional importance. 
IGF-I receptors have been detected in porcine and murine granulosa cells, and 
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IGF-I has been found to stimulate bovine and porcine granulosa cell replication. 
During each menstrual cycle, granulosa cells within follicles must replicate and 
differentiate. Although gonadotrophins and sex steroids are known to function in this 
process, they alone cannot explain why follicles have different responses and ultimate 
fates. Since IGF-I can promote cellular replication and differentiation in various 
tissues and since IGF-I has been found in measurable amounts in follicular fluid, it 
may be an important factor for granulosa cell development. (17) 
Lending further credence to the argument, IGF-I has been shown to have 
several functions in granulosa cell culture. Granulosa cells from immature, 
hypophysectomized, estrogen-treated female rats cultured with 50 ng/mL 
somatomedin-C and 20 ng/mL FSH had significantly higher progesterone 
accumulation compared to treatment with FSH alone. (18) Somatomedin-C augmented 
FSH-stimulated progesterone in a time- and dose-dependent fashion which was 
independent of FSH dose, cellular growth, and cell number. 
In another study by the same investigators, granulosa cells obtained from 
similarly treated female rats were cultured and showed dose- and time-dependent 
increased LH binding with somatomedin-C and FSH compared to somatomedin-C 
alone. The increased binding was due to an increased binding capacity of functional 
receptors.(19) Furthermore, IGF-I and FSH synergistically increase granulosa cell 
aromatase activity, estrogen production, and proteoglycan synthesis which may 
function in antrum formation and follicular atresia. (17) 
Hammond et al retrieved ovaries from four to six month old pigs, aspirated 
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follicular fluid, and obtained granulosa cell samples.(20) They found higher IGF-I 
concentrations in preovulatory follicles than in immature follicles and serum, 
suggesting that at least some in vivo follicular IGF-I originated in the ovary. 
Granulosa cells in vitro also produced IGF-I and IGF-I binding protein. Rat Sertoli 
cells, the male homology to granulosa cells, produce increased IGF-I in the presence 
of GH indicating that extrahepatic synthesis of IGF-I can occur by direct GH 
stimulation. In contrast, rat granulosa cells cultured with FSH did not have increased 
IGF-I.(17) 
Davoren and Hsueh studied hypophysectomized female rats with 
diethylstilbestrol capsule implants.(21) After intraperitoneal injection of 200 ng of 
ovine GH, ovarian, kidney, and serum levels of IGF-I rose. The observers concluded 
that GH appears to directly enhance in vivo ovarian growth factor concentration as 
well as in vitro. Perhaps IGF-I is made by the granulosa cell for its multiple 
purposes and is regulated not only by GRF and GH but also by GnRH. 
GH Secretion during Puberty 
Puberty is a crucial period of human development that illustrates the 
interdependence of growth and reproduction. During this time, secondary sexual 
characteristics develop, and growth rapidly accelerates. Although the precise 
mechanisms regulating the onset of puberty remain unknown, the beginning of 




If delayed, puberty can be induced with pulsatile GnRH that mimics 
physiologic secretion. During pulsatile GnRH treatment, an increase in GH occurs, 
and GH levels correlate with pubertal stage. The predominate explanation is that 
GnRH stimulates LH and FSH which in turn increase estrogen, a known GH 
stimulant. Thus, it is assumed, GH and sex steroids synergistically facilitate the 
growth spurt during puberty.(22) However, the hypothesis that GnRH directly 
stimulates GH secretion independent of estrogen has not been well tested. 
Stanhope et al reported a case of a 16 year old girl with idiopathic 
hypogonadotrophic hypogonadism who was given 2 /xg of GnRH subcutaneously 
every 90 minutes overnight (total dose 12 /xg every 24 hours).(23) After six weeks, 
LH and FSH levels increased, and ultrasound showed an increase in follicular number 
and size. Increased growth velocity in the first three months was associated with an 
increased peak GH level. During that time, GH secretion became largely pulsatile 
with increased amplitude. Induction of puberty by GnRH increased physiologic GH 
secretion. Since the changes occurred over a short time interval, the authors did not 
attribute this effect to sex steroids, but rather to neurotransmitter interactions at the 
hypothalamic level. 
The same researchers later conducted a more complete study of 26 delayed 
puberty patients. They gave pulsatile GnRH intended to mimic physiologic secretion 
by beginning only at night and later increasing the dosages throughout the day. With 
treatment, these patients grew as if they had undergone normal puberty. In addition, 
the timing of the onset of secondary sexual characteristics with the growth spurt 
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approximated normal development. Again, these investigators concluded that the 
increased GH secretion was due not only to sex steroid influence but also to GnRH 
and that GnRH may interact directly with somatotrophs.(24) 
An older study by Sheikholislam and Stempfel involved a family of five with 
dwarfism due to isolated GH deficiency.(25) Each member had characteristic short 
stature and delayed sexual maturation. GH was administered in a dose of 2 mg 
intramuscularly (IM) three times each week. After three to five months, they had 
increased linear growth rates which regressed when treatment ended. Concomitantly, 
each developed secondary sexual characteristics with changes in body hair and libido 
that were not related to gonadotrophin release. These authors concluded that GH may 
alter end organ responses to sex steroids. This study suggests that GH is a necessary 
agent in reproductive maturation and development, in addition to GnRH and 
gonadotrophins. 
GH Secretion in Central Precocious Puberty 
Central precocious puberty (CPP) is a pathologic condition of puberty in which 
the onset of puberty occurs in children less than eight years of age. These children 
have both premature gonadal maturation and a growth spurt characteristic of puberty 
due to early activation of hypothalamic GnRH activity. In girls with CPP, 24 hour 
GH levels are higher than controls and correlate with serum somatomedin-C levels 
and height age compared to chronologic age.(26) For treatment, clinicians use GnRH 
agonists to suppress sexual maturation (27) and slow the exaggerated growth rate. (28) 
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Although GnRH initially stimulates LH and FSH secretion, continuous GnRH down 
regulates its own receptors in the anterior pituitary, eventually causing gonadotrophin 
secretion to diminish.(29) 
Several studies of GnRH treatment for CPP indicate the effects of GnRH on 
growth and GH. Stanhope et al treated eight girls and one boy with CPP with an 
intranasal GnRH analogue (Buserelin).(30) Doses ranged between 17 and 40 
jug/kg/day, and treatment lasted an average of 1.2 years. These patients had 
diminished gonadotrophin pulsatility which reversed gonadal maturation, and the 
researchers predicted an improved height prognosis. 
In a later study, 14 girls with CPP were treated with the same intranasal 
GnRH analogue. The average dose was 28 /xg/kg/day, and treatment lasted for an 
average of 2.3 years. As expected, these subjects achieved diminished secondary 
sexual characteristics, decreased LH pulsatility, and decreased estrogen secretion. 
Initially, during the stimulatory phase of treatment, GH increased. Later, GH 
secretion decreased, due to a change in pulse amplitude not frequency.(31) Although 
the authors did not examine the regulation of GH, they summarily attributed the 
decline to estrogen effects. 
Another study involved five children with CPP. They were given leuprolide 
acetate (Lupron) in a starting dose of 20-30 /xg/kg/day which was adjusted according 
to gonadotrophin response. GH and somatomedin-C levels were measured before and 
six months after treatment. (32) A decline in average GH levels consistent with the 
findings of Stanhope et al was observed in these children.(31) While the number of 
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GH secretory episodes did not significantly change in these children, total GH 
secretion diminished, again indicating a decrease in pulse amplitude not frequency. 
Although these patients had a decreased mean growth velocity, there was no 
significant difference in somatomedin-C levels before and after treatment.(32) 
Mansfield et al studied the effects of 4-8 /xg/kg/day of a GnRH analogue in 10 
girls with CPP.(33) They found LH and FSH suppressed with regression of 
secondary sexual characteristics. During the first year, mean height velocity 
decreased significantly as did the rate of skeletal maturation and the mean peak 
nocturnal GH levels. In addition, mean somatomedin-C levels decreased, contrary to 
the findings of DiMartino-Nardi et al.(32) These effects were reversed upon 
discontinuation of treatment. 
Although the majority of research in this area supports the above findings, not 
all studies concur. When 11 children with CPP were treated with a median dose of 
40 /xg/kg/day of leuprolide acetate for a median time of six months, decreases in LH, 
FSH, estradiol, and growth rate were observed. Decreases in mean basal GH level 
and mean peak GH response to GRF were also found, but there was no significant 
difference in mean IGF-I levels or nocturnal GH concentration. Possible explanations 
for this discrepancy in GH concentration include patient selection, degree of gonadal 




GH and Leiomyomata Uteri 
Leiomyomata are benign uterine tumors and are often treated with GnRH 
analogues to reduce their size. Friedman et al studied 18 premenopausal women with 
leiomyomata in a randomized, placebo-controlled, double blind trial to assess the 
effects of leuprolide acetate-induced hypoestrogenism on serum GH and insulin like 
growth factors.(35) Leuprolide acetate (3.75 mg/month IM depot for four months) 
treated patients had significantly decreased estradiol, GH, IGF-I concentrations, and 
mean uterine volume compared to placebo-treated controls. There was no difference 
in IGF-II concentrations between the two groups. Their study suggests that GH and 
IGF-I, like estrogen, are potential mediators of myometrial growth and further 
supports a connection between growth and reproduction. 
Additional in vitro evidence exists from essentially the same study. Fibroids 
from 17 and myometrial tissue from 10 of the above 18 women who received either 
leuprolide acetate or placebo were cultured, and culture media was assayed for 
hormonal content. The fibroids from women treated with the GnRH agonist secreted 
significantly less IGF-I and IGF-II. However, the IGF-I levels continuously 
decreased over time, while the IGF-II levels were only diminished at 24 hours. As a 
control, total protein content was assayed, and no significant difference was measured 
between the two groups.(36) Thus, long term GnRH administration acts in vitro as 
well as in vivo to diminish the secretion of GH mediators. Whether this result was 
due to the action of GnRH on estrogen or GH was not determined. 
Word et al evaluated the effects of GnRH on estradiol, IGF-I, and GRF- 
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induced GH secretion in adult premenopausal females. (37) Seven women received 1 
mg/day of leuprolide acetate for four weeks during treatment for either uterine 
leiomyomata or ovulation induction, while eight healthy women served as controls. 
They found the mean peak GH response to a GRF bolus was significantly lower in 
GnRH-treated women. Also, GnRH decreased baseline estradiol levels and had no 
significant effect on baseline GH or IGF-I. Because the GH response to GRF was 
positively correlated with estradiol levels, the authors concluded that GnRH-induced 
hypoestrogenism caused diminished GH release. Because of the potential correlation 
with unobserved variables, however, a direct effect of GnRH on GH independent of 
estrogen cannot be dismissed. 
GH and Ovulation Induction 
Normal ovulation requires coordination of the hypothalamic-pituitary axis, its 
feedback signals, and local ovarian responses.(38) Problems can occur at any 
functional level resulting in anovulation and infertility. A promising role for GnRH 
analogues and GH is in the field of ovulation induction for in vitro fertilization (IVF). 
One standard therapy involves treatment with human menopausal gonadotrophins 
(hMG) to stimulate follicle development and human chorionic gonadotrophin (hCG) 
when appropriate to induce ovulation.(29) 
Some women, however, respond with low doses of hMG, while others require 
higher doses. Unfortunately, high doses can be associated with side effects like 
multiple gestations and ovarian hyperstimulation which can be life threatening. GnRH 
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analogues can sometimes be used for hypothalamic-pituitary down regulation in 
women to increase the chance that hMG will be effective.(29) GH-dependent 
production of IGF-I and the recently discovered cellular effects of IGF-I on the ovary 
have led to some clinical success in the addition of GH to ovulation induction 
protocols. GH may diminish the hMG dose necessary to achieve folliculogenesis. 
Menashe et al have shown that the GH response to clonidine administration 
can help predict the subsequent response to hMG needed to induce ovulation.(39) 
Central alpha-adrenergic receptors are involved in the regulation of GH secretion. 
Clonidine, an alpha-adrenergic agent, provokes GH stimulation. Those patients with 
a poor response to clonidine either needed extremely high doses of gonadotrophins or 
completely failed to respond to exogenous gonadotrophins. This study illustrates that 
GH reserve correlates with the ovarian response to hMG. 
One study compared estradiol and GH levels in women treated with hMG to 
those given GnRH (1 mg/day for 14 days) in addition to hMG. Women given both 
GnRH and hMG had higher peak estradiol levels and basal to peak GH increases 
during their menstrual cycle than those given hMG alone.(40) 
An initial study using GH to induce ovulation consisted of seven patients 
resistant to gonadotrophin therapy. They were each given biosynthetic GH (20 IU IM 
on alternate days for two weeks) in addition to hMG. With this treatment, each 
patient had a significant decrease in the required gonadotrophin dose, as well as in the 
length of treatment time. Although there was no change in the number of follicles 
obtained, three women conceived using the combined regimen. GH appeared to 
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increase the ovarian response to gonadotrophin stimulation in women previously 
refractory to gonadotrophin stimulation.(41) 
Blumenfeld and Lunenfeld then reported a case of panhypopituitarism in a 
patient who responded poorly to ovulation induction with the traditional use of hMG 
and hCG.(42) When given GH in addition to hMG, the patient required less hMG 
and conceived during the second cycle. Another case report involved a woman with 
hypothalamic amenorrhea who did not respond to either clomiphene citrate or 
pulsatile GnRH. After treatment with GH (0.1 IU/kg BW) each day in addition to 
pulsatile GnRH, she showed improved follicular recruitment, higher estradiol levels, 
earlier ovulation, and a successful pregnancy.(43) 
Later, in a randomized, placebo-controlled, double blind trial of 16 women, 
Homberg et al tested the effect of GH (24 IU IM on alternate days for two weeks) 
and hMG on ovulation induction.(44) They found, as they had previously, that 
patients who received both hormones had a significant decrease in the required dose 
of hMG and required less time to achieve follicular development. Also, serum IGF-I 
concentrations increased in women receiving GH. They concluded that GH augments 
the ovarian response to gonadotrophin stimulation. Since high GH doses were used, 
however, a question remains whether the GH effect is ultimately physiologic or 
pharmacologic. 
Further support for the use of GH in ovulation induction comes from a study 
of 10 women who were poor responders to a GnRH analogue, hMG, and hCG 
regimen. These patients served as their own controls, because GH was added to their 
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treatment only after three to six months without results. After GH addition, the 
patients needed less hMG, and the treatment time decreased. Follicular growth rate 
increased, and more oocytes were collected, although there was no significant 
difference in estradiol levels or the number of appropriately sized follicles. Six of the 
10 women conceived and delivered healthy babies after receiving GH.(45) 
Despite these studies demonstrating GH augmentation of ovulation induction, a 
recent study by Hughes et al showed that GRF does not act similarly.(46) Twelve 
poor responders were suppressed with a GnRH analogue and then treated with hMG, 
hCG, and 500 fxg of GRF twice daily during the treatment cycle. Although the GH 
and estradiol levels did increase after GRF treatment, serum IGF-I concentrations 
diminished after an initial rise. Follicular fluid IGF-I levels were higher after GRF 
but not significantly. Although GRF treatment caused more follicular development 
and higher oocyte retrieval, no subjects became pregnant. While the hormonal 
environment improved, there was no associated increase in the pregnancy rate. 
Altogether, much of these data describe the interaction between the 
somatotrophic axis and reproductive events. GH and somatomedins are important 
mediators of reproductive development and ovarian function, and GH may be 
complementary to gonadotrophins in ovulation induction. Whether these interactions 
are normally controlled by GnRH remains unknown. GnRH has clearly been shown 
to stimulate GH in a wide variety of human pathological conditions and normal 




MATERIALS AND METHODS 
Experimental Animals: 
Forty sexually-mature female Sprague-Dawley rats weighing 225-250 grams 
were obtained from Charles River Breeding Laboratories, Wilmington, MA. 
Throughout the experimental period, animals were housed in the animal care unit of 
Yale University School of Medicine which provided temperature and photoperiod 
controlled rooms maintained at 22-24 °C with a 12-hour light-dark cycle. The animals 
were maintained on rat chow (Ralston-Purina Co., St. Louis, MO) and tap water ad 
libitum. Care was given according to standard animal care and use guidelines. 
Surgical Procedure: 
Approximately one day after arrival, animals were weighed and anesthetized 
with an intraperitoneal injection of sodium pentobarbital (50 mg/kg BW) (The Butler 
Company, Columbus, OH). Bilateral indwelling intrajugular silastic catheters were 
aseptically placed to allow venous access for bolus infusion and frequent blood 
drawing later in an awake, unstressed animal.(47) 
Through a transverse incision on the ventral side of the neck, the jugular veins 
were exposed. A silastic catheter filled with heparinized saline (90 U/mL) was 
inserted into each internal jugular vein through an incision in the vein’s anterior wall. 
The catheters were positioned in a retrograde fashion with the fenestrated ends 
approximately at the level of the right atrium. When unrestricted blood flow was 
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established in the catheter, the cephalad portion of the vein was ligated, and the 
catheter secured to the vein with 4-0 silk sutures. After catheter function was again 
confirmed, the catheters were filled with a heparin and polyvinylpyrrolidone (1.5 
g/mL PVP) solution. This viscous solution prevents blood from diffusing back into 
the catheter, coagulating, and blocking blood flow during later testing. Next, the 
catheters were sealed with a cap and subcutaneously tunneled around the side of the 
neck to protrude dorsally through a second skin incision. To prevent the animals 
from destroying the lines, the indwelling catheters were taped together and stapled on 
top of the animal’s back. All incisions were closed with staples, and each animal was 
housed individually after surgery to prevent catheter removal. All animals gained five 
to 30 grams of body weight post-operatively and were thus assessed to have 
adequately recovered. 
Study Design: 
Approximately five days after surgery, the animals were moved from the 
animal care facility to the laboratory for testing. They were weighed and randomly 
assigned to one of four groups: I) 0.9% normal saline control, II) human GnRH 0.1 
jtg/g BW (Factrel, Wyeth-Ayerst Laboratories, Philadelphia, PA), III) Apomorphine 2 
nM/g BW (A-4393, Sigma Chemical Company, St. Louis, MO) plus GnRH 0.1 jxg/g 
BW, or IV) Somatostatin 2 nM/g BW (SRIF-14, 5-8769, Sigma Chemical Company, 
St. Louis, MO) plus GnRH 0.1 /xg/g BW. 
At the beginning of the study, the heparin/PVP solution, now hardened, was 
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aspirated from one venous catheter, and the external tip of the catheter was attached 
to a heparinized saline (50 U/mL) filled polyethylene line. To help maintain catheter 
patency, a syringe was attached to the other end of the line which was periodically 
flushed. The line extended outside the cage to allow the awake animal complete 
freedom of movement throughout the study period. If blood did not easily flow 
through the first catheter, the second catheter was used. 
To avoid dilution errors and insure complete drug administration, 
approximately 1 mL of blood was removed prior to each injection or sample 
withdrawal and then returned to the animal. Blood was withdrawn (1 mL) through 
the catheter and was immediately centrifuged for 15 seconds (Brinkmann Centrifuge 
3414). This time 0 (baseline) serum was pipetted off and stored frozen at -80°C for 
later assays. The remaining blood cells were resuspended to a volume of 1 mL with 
saline and the assigned experimental substance according to treatment group (Table 1, 
Compound 1). This solution was injected through the catheter. Removed red blood 
cells were always returned to the animal in order to keep the circulating blood volume 
constant and prevent anemia. Within five minutes, a second intrajugular injection of 
1 mL normal saline with or without GnRH was injected, again according to study 
group (Table 1, Compound 2). 
After the injections, every 30 minutes for a total of 120 minutes, 1 mL of 
blood was withdrawn and centrifuged, yielding approximately 400 /*L of serum. 
Again, sera were frozen and cells reinfused when suspended to a volume of 1 mL in 




At the end of the study period, vaginal wet smears were obtained to determine 
estrus cycle day by light microscopy. A majority of cornified cells indicated estrus, a 
leucocytic smear indicated metestrus, and epithelial cell predominance indicated 
proestrus. Diestrus was signified by a relatively acellular smear with a mixture of all 
cell types.(48) Rats were sacrificed by an intravenous bolus of pentobarbital. 
Hormone Measurements: 
After completion of all in vivo studies, sera were divided into four aliquots of 
100 fxh. Each portion was placed in a separate tube and stored at -80°C. Rat LH 
and GH were measured using radioimmunoassay (RIA) kits provided by the National 
Hormone and Pituitary Program, National Institute of Diabetes and Digestive and 
Kidney Diseases, University of Maryland School of Medicine. Samples were 
measured in duplicate within the same assay. Necessary solutions included PBS (10 
mM sodium phosphate, 150 mM sodium chloride, and 0.1% sodium azide at pH 7.6) 
and RIA buffer (1% bovine serum albumin in PBS). Dilution experiments were 
performed for each assay to determine appropriate antibody concentrations achieving 
substrate excess and adequate separation. 
NIDDK-rLH-I9 was iodinated with 12SI (New England Nuclear Research 
Products, DuPont Company, Boston, MA) by the lactoperoxidase method for the LH 
RIA.(49) Each tube contained approximately 10,000 cpm/0.1 mL RIA buffer (trace). 
NIDDK-anti-rLH-s-10 in 2% normal rabbit serum (Sigma Chemical Company, St. 
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Louis, MO) was used as the initial antibody in a dilution of 1:40,000. NIDDK-rLH- 
RP-3, used to generate a standard curve, was diluted in 0.1 mL RIA buffer and used 
in quantities ranging from 0.05 ng to 10 ng. Sample tubes contained 50 /xL of serum, 
and the total volume in each tube was 0.4 mL. The final antibody dilution was 
therefore 1:160,000. 
After addition of all reagents (RIA buffer, standard or sample, trace, and 
antibody), the tubes were incubated at room temperature overnight. To separate the 
bound antibody-antigen complex from the unbound, 100 /iL of a 1:20 dilution of goat 
anti-rabbit immunoglobulin (AB21, Chemicon International Company, Temecula, CA) 
in PBS was added to the tubes which then incubated for two hours again at room 
temperature. To aid the precipitation, 1.0 mL of cold polyethylene glycol (6% in 
PBS) was then added. Tubes were vortexed, incubated for five minutes, and 
centrifuged at 2,500xg for 15 minutes at 4°C (Sorvall RT6000 Refrigerated 
Centrifuge, DuPont Company). At this point, the supernatant was aspirated and the 
pellet counted by Automatic Gamma Counter (Micromedic Systems 4/200) for one 
minute. The counts per minute were transformed by a computerized program using 
four parameter weighted logit-log regression analysis.(50) 
All samples were analyzed in four separate assays with an average ED50 of 
494.75. The average intra-assay coefficients of variation (CV) for the LH assay were 
13.5%, 12.6%, and 24.3% at 20%, 50%, and 80% B/Bo respectively. An external 
standard was not used. 
For the GH assay, NIDDK-rGH-I-7 was iodinated with 125I (New England 
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Nuclear Research Products, DuPont Company, Boston,MA) by the chloramine-T 
method.(51) Again, each tube contained approximately 10,000 cpm/0.1 mL RIA 
buffer. NIDDK-anti-rGH-S-5 in 2% normal monkey serum (Antibodies Incorporated, 
Davis, CA) was used as the first antibody in a dilution of 1:3750. NIDDK-rGH-RP-2 
produced a standard curve ranging from 0.1 ng to 10 ng/Q.l mL RIA buffer. Again, 
50 juL serum samples were used in a total volume of 0.4 mL bringing the final 
antibody dilution to 1:15,000. 
The assay for GH followed the same procedure as LH, however, the second 
antibody for separation was 100 fxL of 1:20 goat anti-monkey immunoglobulin (P3, 
Antibodies Incorporated, Davis, CA) in PBS. Again, all the samples were measured 
in four assays with an average ED50 of 865.75. Rat GH average intra-assay CV was 
10.5%, 9.7%, and 18.7% for 20%, 50%, and 80% B/Bo, respectively. The 
interassay coefficient of variation was 5.2%. All hormone levels are reported as the 
mean ± standard errors of the mean (SEM). 
Statistical Analysis: 
Any serum sample with an LH level below the limit of assay sensitivity (0.5 
ng/mL) was assigned a value of 0.5 ng/mL. For the GH assay, the lower limit of 
detection was 1.2 ng/mL, and again, samples with GH levels below this limit were 
assigned this value. Hormone data were analyzed with Systat (SYSTAT Intelligent 
Software, Evanston, IL). Repeated measures analysis of variance (RM-ANOVA) and 
one- or two-tailed student’s t-tests were used, as indicated. Because a normal 
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distribution of data was confirmed by the Lilliefors test of normality, parametric 
analysis was used. RM-ANOVA allows comparison of subjects under repeated 
measures over time. Probabilities <0.05 were considered significant. 
Participants: 
I performed surgery on all animals involved in this study and with Dr. Alan S. 
Penzias, undertook the necessary experimental interventions. I received instruction on 
specific surgical techniques from Dr. Gabriele Rossi. Dr. Raymond F. Aten 
iodinated rat LH and GH and defined the LH assay protocol. I developed the GH 




The forty animals were divided into four treatment groups as follows: 10 
received normal saline, 16 got GnRH alone, 10 were injected with GnRH plus 
apomorphine, and four received GnRH with somatostatin. Due to the unavoidable 
financial constraints of this initial study, animals were assigned to treatment groups in 
unequal numbers. Specifically, the high cost of somatostatin compared to other 
treatment compounds limited this group to only four animals. When occasional 
difficulties were encountered withdrawing blood, time points were omitted from 
statistical analysis. 
Table 2 indicates the number of animals in each estrus cycle day by treatment 
group. Analysis of results by estrus cycle day was not useful because the number of 
animals in each treatment group were not large enough for meaningful statistical 
comparison. Thus, the LH and GH values for each group were averaged to include 
all cycle days. Since estrogen levels vary with estrus cycle day and since estrogen 
stimulates GH, GH levels in female rats may vary with day of estrus. 
Over the two-hour study period, GnRH caused a significant elevation in LH 
levels as a function of time (Figure 1) (n = 14, p<0.0005). The mean basal LH level 
was 0.62 ± 0.05 ng/mL and rose to a maximum of 17.1 ± 2.7 ng/mL at 90 minutes. 
When animals were pretreated with apomorphine, GnRH-induced LH levels 
were significantly diminished. From a mean basal LH level of 0.71 ±0.11 ng/mL, 
LH peaked to only 10.6 ± 1.9 ng/mL again after 90 minutes. Although these 
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animals responded to GnRH with an LH elevation, at 60, 90, and 120 minutes the LH 
levels were all significantly lower than in animals receiving only GnRH (n = 8, 
p<0.05). 
Somatostatin pretreatment, however, did not affect the GnRH-induced LH rise. 
These animals had a mean basal LH level of 0.5 ng/mL, which at 90 minutes rose to 
a maximum of 26.7 + 6.5 ng/mL (n=4, p< 0.0005). When these animals were 
compared to those receiving only GnRH, there was no statistically significant 
difference in LH concentration at 60, 90, or 120 minutes (p>0.05). 
The mean serum LH concentration in saline treated animals ranged from 0.95 
± 0.33 ng/mL at time 0 to 1.9 ± 1.2 ng/mL at 120 minutes. There was no 
statistically significant difference in LH levels as a function of time for this control 
group using RM-ANOVA (n = 8, p>0.05). 
In addition to stimulating LH levels, GnRH also caused a significant rise in 
serum GH levels as a function of time (Figure 2) (n = 14, p< 0.0005). After 
administration of GnRH, the mean basal GH level of 3.9 ± 1.5 ng/mL increased to a 
maximum of 26.6 ± 3.7 ng/mL at 90 minutes. 
When apomorphine was added to GnRH treatment, GH levels were still 
stimulated over time in contrast to the blunting effect on LH (n=9, p< 0.0005). The 
mean basal serum GH level in this group was 18.2 + 6.5 ng/mL, which fell to 3.7 + 
0.8 ng/mL at 30 minutes, rose to a maximum of 37.1 ± 7.1 ng/mL at 60 minutes, 
and then fell again over the next hour. Comparing this group to the GnRH-only 
group, neither is consistently higher or lower than the other. Although there is a 
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difference between the groups for one time point, the other four time points are not 
significantly different (p>0.05). 
Nevertheless, somatostatin clearly diminished the GnRH-induced GH response. 
This treatment group had mean serum GH levels that remained almost constant over 
time (n=4, p>0.05) with a minimum of 1.2 ng/mL at 30 minutes and a maximum of 
5.7 ± 4.3 ng/mL at 90 minutes. When compared to animals given GnRH alone, this 
group had a significantly lower GH response (p<0.01). 
The saline treated animals had varying GH concentrations over time, from 4.5 
±1.6 ng/mL baseline to 22.8 ± 8.9 ng/mL at time 90. Despite this wide range in 
values, RM-ANOVA did not detect a statistically significant difference in GH level as 




GnRH has been known to stimulate gonadotrophin secretion in a wide range of 
species including goldfish, rats, and humans. GnRH increases synthesis and storage 
of gonadotrophins, moves gonadotrophins from a reserve pool to a secondary pool, 
and directly releases gonadotrophins from the pituitary. Normally, the arcuate 
nucleus secretes GnRH in a pulsatile fashion to control the reproductive cycle and 
receives negative feedback from gonadotrophins and sex steroids. When GnRH is 
given to humans as an IV bolus, serum LH rises within five minutes, peaks at 20-25, 
and then returns to baseline over a few hours.(52) 
GnRH has also been found to stimulate human GH secretion, but most of these 
observations have been limited to pathologic conditions such as acromegaly (6,7), 
anorexia nervosa (8), Klinefelter’s syndrome (9), diabetes mellitus (10,12), and 
depression (11). Alternatively, long-term GnRH analogue treatment down regulates 
gonadotrophins and has been associated with decreased GH secretion. This evidence 
is documented in studies performed on subjects with central precocious puberty 
(32,33), leiomyomata (35,36), and infertility (37). 
This study of awake, chronically catheterized rats provides evidence that 
GnRH significantly increases both serum GH and LH as a function of time. 
Apomorphine, a dopamine receptor agonist, selectively decreased the LH response to 
GnRH without affecting GH. On the other hand, somatostatin successfully blocked 
GnRH-induced GH secretion but did not change LH. Because GH can be 
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independently blocked without affecting LH and because LH can be separately 
diminished without changing GH, GnRH’s action appears specific to each anterior 
pituitary hormone. Thus, this study suggests that GnRH induces independent 
secretion of LH and GH. 
Overall, these findings are consistent with those of Marchant et al in their 
study of GH regulation in goldfish, although differences exist between GH peaks and 
time course.(15) They found GH levels elevated to 100 ng/mL at three, six, nine, 
and 24 hours post injection. The present results were obtained over a two hour time 
period using identical drug dosages to those effective in goldfish. During this time, 
both GH and LH were stimulated to peaks of 20-30 ng/mL which then began to fall. 
Within two hours, however, the levels had still not returned to baseline. These 
effects over time are more consistent with human data in acromegalics (6), depressed 
patients, and healthy volunteers.(11) It is not clear whether the fall in GH and LH at 
the 120 minute time point represents a real trend toward baseline or a momentary 
decline during a longer, continuous rise. This decline may be due to GnRH clearance 
or simply the release of stored pools of GH and LH. A possible explanation for the 
different time periods between studies is the likely difference in clearance rates of 
mammalian GnRH in goldfish compared to rats. If the present study had observed a 
longer time period, perhaps a true return to baseline could have been demonstrated. 
Alternatively, a second peak might have been discovered which could represent new 
GH and LH synthesis. 
While it seems clearer that GnRH may induce mammalian GH secretion, GH 

31 
secretion itself is sensitive to circulating sex steroids. In humans, estrogen alone 
stimulates GH. This effect is illustrated by a study of estrogen replacement (20 
jug/day ethinyl estradiol for 15 days) in 17 postmenopausal healthy women. After 
estrogen treatment, the women’s mean resting GH level and 22 hour GH secretion 
significantly increased. Exercise-induced and GRF-induced GH secretion increased as 
well.(53) 
Rats also exhibit estrogen-dependent GH secretion. When male rats were 
gonadectomized, the amplitude of GH pulses decreased. When these rats were 
implanted with estradiol containing silastic capsules, their basal GH increased. 
Furthermore, they displayed a female-like pattern of GH secretion characterized by 
more frequent, lower amplitude pulses compared to the male-like higher amplitude 
bursts.(54) With pituitary autotransplantation to the kidney capsule, estradiol still 
caused a dose-dependent increase in GH levels. (55) 
An initial in vitro study of estrogen effects on rat GH secretion used cultures 
of rat pituitary tumor cells that actively produced GH. Estradiol in milli- and micro¬ 
molar concentrations caused a dose-dependent and reversible decrease in GH secretion 
over 24 hours.(56) Other in vitro studies using normal pituitary cell cultures also 
contradict in vivo findings. Webb et al found that estradiol had no effect on basal or 
GRF-induced GH secretion in male rat pituitary cells.(57) Fukata and Martin later 
found no influence of estradiol on GRF-induced GH secretion in female rat pituitary 
cells. (58) 
Still, many in vitro studies support the in vivo findings. In normal female 
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pituitary cell cultures, 0.5 ^g/mL estradiol doubled the GH release after a three hour 
incubation.(59) Similarly, another study of normal female pituitary cell culture 
revealed that estradiol, as well as estrone and estriol, caused significant increases in 
spontaneous and GRF-stimulated GH release after 72 hours.(60) Current evidence 
obtained by Shirasu et al from immunostained hypothalami and pituitaries from 
ovariectomized rats exposed to increasing estrogen concentrations indicates that 
certain GRF neurons are estrogen targets.(61) They concluded that estrogens may 
function in GH regulation by modulating GRF release. 
What remains unclear is whether the effect of GnRH on GH is due to these 
estrogen effects alone or whether GnRH can act directly at the hypothalamic or 
pituitary level to regulate GH secretion. When long-term GnRH administration in 
humans diminishes gonadotrophin and estrogen synthesis, it has also been shown to 
diminish GH secretion.(32,33,35,36) In demonstrating that GnRH induces GH 
independent of LH, the present study suggests that the effect of GnRH on GH is not 
secondary to LH-induced estrogen. Future investigation of the effects of GnRH on 
GH independent of estrogen status is needed to address this question. 
Rats in different estrus stages have varied estrogen levels. In proestrus, there 
is a peak of estradiol to approximately 40 pg/ml which falls to a baseline of about 10 
pg/ml in estrus. Throughout diestrus and metestrus estradiol levels gradually rise. 
Corresponding to this, LH levels peak at 35 ng/ml during proestrus and return to 
baseline by the beginning of estrus. LH levels remain at a baseline of about 1 ng/ml 
during diestrus and metestrus.(62) Normal rats exhibit pulsatile GH release which in 
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males has been shown to peak at greater than 200 ng/mL and decline to less than 1 
ng/mL. In male rats, a pulse of GH secretion occurs approximately at 3.3 hourly 
intervals. Female rats have more continuous GH secretion with lower peaks and 
higher troughs.(63) The timing of these GH surges is associated with the light-dark 
cycle. (64) 
For statistical analysis, within the present study, animals in different estrus 
stages were grouped together by treatment. Using this approach, results obtained 
were statistically significant. It is unlikely that the LH peaks obtained soon after 
GnRH administration were simply due to spontaneous secretion. If significant 
spontaneous secretion of LH had occurred, the saline-treated control rats should have 
manifested the same increases, which they did not. 
Although the saline-treated control rats did not have a statistically significant 
GnRH-induced GH rise as a function of time by RM-ANOVA, there appears to be 
some increase in GH in this group, especially at 90 minutes, as illustrated in Figure 
2. As a sample size increases it becomes a better representation of the population 
from which it is taken. Thus, more reliable statistics are obtained from larger sample 
sizes. The failure of the saline group to achieve significance may simply be a 
problem with the sample size. Working within the constraints of limited funding 
necessarily decreased the sample sizes in this study. Perhaps if a larger sample size 
had been used with equal numbers of animals in each group, statistically significant 
differences in saline-induced GH would have been detected. 
Alternatively, spontaneous estrogen-induced GH secretion might account for 

34 
the apparent increase in GH in the saline-treated group and the statistically significant 
rise in the GnRH-treated group. Two of 10 (20%) saline-treated animals were in 
proestrus, whereas four of 16 (25%) GnRH-treated animals were in proestrus. It is 
possible that the slightly higher percentage of proestrus animals in the GnRH-treated 
group resulted in a statistically significant rise in GH. If the saline-treated group also 
had 25% of animals in proestrus, then perhaps a statistically significant rise in GH 
would have been obtained from saline alone. Again, a larger sample size might allow 
differences in estrus cycle day to be discerned. Future experiments may also involve 
stricter time of day control for better synchronization of estrus cycle phase. 
Furthermore, vaginal smears should be done every day to follow cytology over a 
longer period of time since a single smear is not sufficient to accurately determine day 
of estrus and since a surgical procedure can disrupt normal estrus patterns. Another 
method to determine estrogen status more accurately would simply be to measure 
estrogen levels in addition to LH and GH. To eliminate the effect of estrogen on GH 
altogether, future studies could use ovariectomized animals to determine the effect of 
GnRH on GH. 
Estrogen is not unique in its ability to stimulate GH secretion. Multiple other 
physiologic and pathologic states and mediators have similar effects. Exercise, sleep, 
hypoglycemia, pain, vasopressin, glucagon, neurotensin, endorphins, metenkephalin, 
gastrin, catecholamines, sedatives and anesthetics can all increase circulating GH 
concentrations.(5) GH regulation is indeed complex, and it remains difficult to 
strictly control for everything that influences it. 
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In contrast to humans, stress causes inhibition of GH secretion in rats.(64) 
Stress increases somatostatin thereby decreasing GH. In the present study, stress 
cannot account for the increased serum GH levels in saline-treated animals. Prolactin 
levels in rats do increase in response to stress. An estimation of the animal’s stress 
may be obtained in future investigations by measuring prolactin levels in addition to 
GH and LH. 
Although little controversy exists about somatostatin’s ability to inhibit GH in 
different species, the effect of apomorphine on GH is less certain. As a dopamine 
agonist, apomorphine has been shown to increase GH in men but appears less 
effective in women. Reserpine, which depletes norepinephrine and dopamine stores, 
decreases rat GH levels. Whereas clonidine overcomes this and stimulates GH, 
apomorphine is not effective. Thus, in the rat, the alpha-adrenergic system appears to 
play a more substantial role in GH regulation than does the dopamine pathway.(5) In 
female rat pituitary cell culture, dopamine itself had no effect on GH secretion.(59) 
In the present study apomorphine did not consistently change the GH response to 
GnRH in a statistically significant manner, but the complex response obtained 
suggests that other factors already discussed may be involved. 
The ability of apomorphine to inhibit gonadotrophins in goldfish, humans, and 
rats is well documented. In normal female goldfish, intraperitoneal injection of 
dopamine and apomorphine significantly decrease serum gonadotrophins after one 
hour and six hours, respectively. After fish were given GnRH and apomorphine 
together, their serum gonadotrophin levels were significantly lower than with GnRH 
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alone.(65) Domperidone, a specific D2 receptor antagonist, increases gonadotrophins 
in male and female goldfish at a dose of 10 /xM/kg BW.(66) In cultured goldfish 
cells, apomorphine inhibited the gonadotrophin response to GnRH. Although 
apomorphine is a non-selective dopamine agonist, experiments using selective agonists 
and antagonists show that the mechanism is D2 receptor mediated.(67) 
In a study using eight normal males and females, a 4 /xg/kg/min IV dopamine 
infusion over three hours caused a significant decrease in circulating LH and prolactin 
levels. The LH rose rapidly upon cessation of the infusion. No significant changes 
in FSH levels were found, and GH levels fluctuated randomly.(68) In ovariectomized 
rats, apomorphine (1.5 mg/kg) inhibited episodic LH secretion for one hour.(69) The 
findings of the present study in rats are consistent with these cross species results. 
Apomorphine significantly blunted the LH response to GnRH. 
Where GnRH acts on the hypothalamic-pituitary axis to cause GH release was 
not addressed in this study. Evidence does exist, though, to support GnRH action at 
the pituitary level. Marchant et al found that goldfish pituitary fragments exposed to 
GnRH in vitro had dose-dependent increased GH secretion.(15) Panerai et al 
transplanted rat anterior pituitaries under the renal capsule after hypophysectomy.(70) 
The rats were exposed to 0.6 and 1.2 jxg of GnRH and after five and 10 minutes had 
increased GH levels. An intact hypothalamic-pituitary portal blood system was not 
required for GnRH-induced GH secretion. 
Future experiments to determine where GnRH affects GH are required. Using 
in situ hybridization techniques, the present study could be repeated using only 
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GnRH, and probes for mRNA to rat GRF and GH could be used in the hypothalamus 
and pituitary, respectively. If GnRH induces hypothalamic production of rat GRF 
mRNA, it will indicate paracrine stimulation of a hypothalamic trophic factor by 
another hypothalamic trophic factor. If GnRH acts in an endocrine mode, pituitary 
production should be detected by rat GH mRNA. Otherwise, if increased mRNA 
synthesis is not detected in either the hypothalamus or the pituitary, the most likely 
explanation would be that GnRH caused the release of accumulated pituitary GH 
stores. 
GH appears to play an important role in various reproductive events—from 
granulosa cell replication and differentiation to sexual development and ovulation 
induction. Previous studies describe GnRH-induced GH secretion in clinical 
conditions as an abnormal or paradoxical response. The present study provides 
evidence that GH secretion may be induced by GnRH independent of its effect on LH 
in normal female rats similar to the findings in normal female goldfish. These results 
provide a functional explanation for how GH and possibly IGF-I are involved in a 
mammalian reproductive system. 
If GnRH does indeed have a direct stimulatory action on human GH, certain 
mechanisms would become clearer. In puberty, for instance, the association between 
secondary sexual characteristics and accelerated growth could be explained by the 
onset of hypothalamic GnRH pulses, stimulating both GH and gonadotrophins. 
Similarly, normal follicular development and fertility may depend on adequate GnRH 
to stimulate not only gonadotrophins but also GH. And finally, granulosa cell 
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replication and differentiation, which appears dependent on IGF-I, may actually be 
regulated directly by GnRH via GH. The findings and preliminary conclusions of the 
present study will enable future research to elucidate these effects in normal humans 
and provide further understanding of GH regulation. 
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Compound 1 was injected into the animal at time 0 in 1 mL reconstituted 
blood. 
Compound 2 was injected into the animal within five minutes of Compound 1 
in a total volume of 1 mL. 
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TABLE 2: Number of Animals in Each Estrus Day by Treatment Group 
TREATMENT GROUP 
I II III IV 
ESTRUS DAY 




estrus 2 2 1 0 
diestrus 1 4 3 1 
metestrus 5 6 3 3 





FIGURE I: LH Concentration vs. Time 






FIGURE 2 : GH Concentration vs. Time 
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